Roche Licenses PI3K Biomarker from Qiagen | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche today announced it has obtained a global co-exclusive license for phosphoinositide 3-kinase, a biomarker for cancer, from Qiagen.

Roche plans to develop real-time and endpoint PCR diagnostic assays for PI3K to run on its cobas 4800 System, it said in a statement. The biomarker was licensed exclusively by Johns Hopkins University, which owns its patent, to DxS, a wholly owned subsidiary of Qiagen. DxS is now called Qiagen Manchester.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.